FDA alerts against using Celltrion's DiaTrust COVID-19 Ag Rapid Tests due to risk of false results; test has not been authorized, cleared or approved by the FDA

Sample article from our Tissue & Hygiene

March 2, 2022 (press release) –

 

The U.S. Food and Drug Administration (FDA) is warning people not to use certain Celltrion USA Inc. DiaTrust COVID-19 Ag Rapid Tests. People should not use the Celltrion DiaTrust COVID-19 Ag Rapid Test that is in green and white packaging (see image below). This test has not been authorized, cleared, or approved by the FDA for distribution or use in the United States. The FDA is concerned about the risk of false results when using this unauthorized test.

The FDA has not received reports of injuries, adverse health consequences, or death associated with use of this unauthorized Celltrion USA DiaTrust COVID-19 Ag Rapid Test.

Recommendations

  • If you have a Celltrion DiaTrust COVID-19 test, compare the packaging to the image above of the unauthorized test. Do not use Celltrion DiaTrust COVID-19 tests that come in green and white packaging.
  • Test users and caregivers: Talk to your health care provider if you think you were tested with the Celltrion DiaTrust COVID-19 Ag Rapid Test and you have concerns about your test results.
  • Health care providers and testing program organizers: If an antigen test was performed less than two weeks ago using the Celltrion DiaTrust COVID-19 Ag Rapid Test, consider retesting your patients using an FDA authorized SARS-CoV-2 diagnostic test if you suspect an inaccurate result. If testing was performed more than two weeks ago and there is no reason to suspect current SARS-CoV-2 infection, it is not necessary to retest.
  • Report any problems you experience with the Celltrion DiaTrust COVID-19 Ag Rapid Test to the FDA, including suspected false results. See Reporting Problems with Your Test.

Test Descriptions

  • The unauthorized Celltrion DiaTrust COVID-19 Ag Rapid Test uses a mid-turbinate nasal swab sample to detect proteins, called antigens, from SARS-CoV-2, the virus that causes COVID-19. This unauthorized test has the same name as an FDA authorized version of the test for point of care settings but is not the same test. The unauthorized test has a green and white box.
  • The Celltrion DiaTrust COVID-19 Ag Home Test was authorized by the FDA on October 21, 2021 for home use. These tests are not affected by this Safety Communication and can continue to be used.
  • The Celltrion DiaTrust COVID-19 Ag Rapid Test was authorized by the FDA on September 1, 2021, for point-of-care use, such as in health clinics. These tests are not the subject of this Safety Communication and can continue to be used.
  • Please refer to the authorized labeling for the DiaTrust COVID-19 Ag Home Test and the DiaTrust COVID-19 Ag Rapid Test to confirm that the test you’re using is FDA authorized.

Risks of False Test Results

  • A false-negative antigen test result means that the test says the person does not have COVID-19 but they actually do have COVID-19. A false-negative result may lead to delayed diagnosis or inappropriate treatment of SARS-CoV-2, which may cause people harm including serious illness and death. False-negative results can also lead to further spread of the SARS-CoV-2 virus, including when people are housed together in health care, long-term care, and other facilities based on these false test results. When false negative test results are received, actions to limit exposure to an infected person might not be taken, such as isolating people, limiting contact with family and friends, or limiting access to places of employment.
  • A false-positive antigen test result means that the test says the person has COVID-19 but they are actually do not have COVID-19. A false-positive result may lead to a delay in both the correct diagnosis and appropriate treatment for the actual cause of a person’s illness, which could be another life-threatening disease that is not COVID-19. False-positive results could also lead to further spread of the SARS-CoV-2 virus when presumed positive people are housed together.

FDA Actions
The FDA regularly monitors the marketing of unauthorized, unapproved, or uncleared tests, including reports of problems with test performance or results. The FDA is working with Celltrion USA, Inc., to resolve this safety issue.

Celltrion USA, Inc., issued a recall for all unauthorized DiaTrust COVID-19 Ag Rapid Tests that were distributed in the U.S., which includes at least 162,000 unauthorized tests.

The FDA will continue to keep the public informed of significant new information.

Reporting Problems with Your Test
If you think you had a problem with a SARS-CoV-2 test, the FDA encourages you to report the problem through the MedWatch Voluntary Reporting Form.

Health care personnel employed by facilities that are subject to the FDA’s user facility reporting requirements should follow the reporting procedures established by their facilities.

Questions?
If you have questions about this Safety Communication, email the Division of Industry and Consumer Education (DICE) at DICE@FDA.HHS.GOV or call 800-638-2041 or 301-796-7100.

Content current as of:
03/01/2022

Regulated Product(s)
MIL OSI USA News -

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Jason Irving
Jason Irving
- SVP Enterprise Solutions -

We offer built-to-order tissue & hygiene coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.